The 2024 Drug Price and Affordability Landscape
The Johns Hopkins Bloomberg School of Public Health will host an expert briefing for the media from 2 p.m. to 2:30 p.m. EST on Wednesday, January 24, via Zoom, featuring Gerard Anderson, PhD and Mariana P. Socal, MD, PhD, who will discuss drug prices, access, and affordability in the U.S. In just one year, prices for more than 4,200 prescription drugs increased, on average, by 15.2%.
Topics will include:
- The Biden administration’s plan to exercise march-in rights (a funding agency’s power to intervene) on taxpayer-funded drugs.
- Where Medicare drug price negotiations stand.
- How the recent spate of pharmacy closures will affect consumers.
- New advice/rules for pharmacy benefits in 2024.
- The recent FDA ruling on drug imports from Canada.
Experts:
- Gerard Anderson, PhD, professor in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health
- Mariana P. Socal, MD, PhD, associate scientist in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health
Registration required: Please register here by 10 a.m. EST on Wednesday, January 24, to receive the Zoom link and password. Questions may be submitted via the registration form or via chat during the briefing.
###
Resources:
- Medicare Drug Price Negotiation Program
- Maryland Prescription Drug Affordability Board
- Johns Hopkins Drug Access and Affordability Initiative
- Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries
- Gerard Anderson, Commonwealth Fund
- Mariana Socal, Council for Informed Drug Spending Analysis
- Mariana Socal, World Health Organization Technical Advisory Group on Pricing Policies for Medicines
- Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations
RSS